Arcturus Therapeutics
ARCT
38 hedge funds and large institutions have $46.6M invested in Arcturus Therapeutics in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
23% more funds holding
Funds holding: 31 → 38 (+7)
19% more call options, than puts
Call options by funds: $53.4M | Put options by funds: $44.8M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
23% less capital invested
Capital invested by funds: $60.3M → $46.6M (-$13.6M)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GL
GLG LLC
New York
|
+$4.47M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$2.42M |
| 3 |
Millennium Management
New York
|
+$1.63M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$781K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$655K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.2M |
| 2 |
JP Morgan Chase
New York
|
-$4.02M |
| 3 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$2.91M |
| 4 |
SC
Sophrosyne Capital
New York
|
-$2.68M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$2.44M |
ARCT Hedge Fund Activity: Q3 2014 in Review
38 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2014, worth a combined $46.6M — down 23% from $60.3M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ARCT positions and 7 closed out — a net gain of 7 holders — while 7 added to existing stakes and 15 trimmed.
The largest buyer was GLG LLC, opening a new position worth an estimated $4.47M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.2M sold.
- 38 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2014, up from 31 in Q2 2014.
- Funds reported $46.6M of Arcturus Therapeutics stock for Q3 2014, down 23% quarter-over-quarter.
- 14 funds opened new Arcturus Therapeutics positions in Q3 2014 and 7 closed out, a net change of +7 holders.
- The largest Arcturus Therapeutics buyer in Q3 2014 was GLG LLC, an estimated $4.47M added.
- The largest Arcturus Therapeutics seller in Q3 2014 was Great Point Partners, an estimated $6.2M sold.
Based on aggregated 13F filings for Q3 2014.